Krystal Biotech, Inc. (NASDAQ:KRYS) Given Average Recommendation of “Buy” by Brokerages

Krystal Biotech, Inc. (NASDAQ:KRYS) has received a consensus rating of “Buy” from the eight research firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $220.00.

Several research analysts have recently weighed in on the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price objective on shares of Krystal Biotech in a research report on Thursday, February 20th. Jefferies Financial Group initiated coverage on Krystal Biotech in a research note on Wednesday, March 5th. They issued a “buy” rating and a $245.00 price target on the stock. Chardan Capital raised their price objective on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research report on Thursday, February 20th. Citigroup boosted their target price on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research report on Thursday, February 20th. Finally, HC Wainwright restated a “buy” rating and issued a $221.00 price target on shares of Krystal Biotech in a report on Friday, February 28th.

Krystal Biotech Price Performance

Krystal Biotech stock opened at $160.65 on Friday. The firm has a market cap of $4.63 billion, a P/E ratio of 53.73 and a beta of 0.75. The stock’s 50 day moving average is $173.88 and its 200 day moving average is $172.35. Krystal Biotech has a one year low of $141.72 and a one year high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, February 24th. The company reported $1.52 EPS for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million. During the same period in the prior year, the firm posted $0.30 EPS. The company’s quarterly revenue was up 116.4% on a year-over-year basis. Equities analysts anticipate that Krystal Biotech will post 6.14 earnings per share for the current fiscal year.

Insider Buying and Selling at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the transaction, the insider now owns 1,463,711 shares of the company’s stock, valued at $260,233,178.69. The trade was a 1.68 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CAO Kathryn Romano sold 750 shares of the company’s stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the sale, the chief accounting officer now owns 12,604 shares of the company’s stock, valued at $2,208,472.88. This trade represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. Insiders own 14.10% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Wilmington Savings Fund Society FSB bought a new stake in Krystal Biotech in the 3rd quarter worth about $40,000. GF Fund Management CO. LTD. bought a new position in shares of Krystal Biotech during the 4th quarter worth approximately $95,000. Covestor Ltd boosted its stake in shares of Krystal Biotech by 972.7% in the 4th quarter. Covestor Ltd now owns 708 shares of the company’s stock worth $111,000 after buying an additional 642 shares during the last quarter. Avanza Fonder AB bought a new position in shares of Krystal Biotech in the fourth quarter valued at approximately $119,000. Finally, KBC Group NV increased its position in shares of Krystal Biotech by 46.3% during the fourth quarter. KBC Group NV now owns 939 shares of the company’s stock valued at $147,000 after acquiring an additional 297 shares during the last quarter. 86.29% of the stock is owned by institutional investors.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).